Patents by Inventor Stephen A. Cockle
Stephen A. Cockle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6168928Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: May 21, 1998Date of Patent: January 2, 2001Assignee: Connaught Laboratories LimitedInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 6018022Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: January 25, 2000Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5977304Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: November 2, 1999Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5965385Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5856122Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: August 22, 1994Date of Patent: January 5, 1999Assignee: University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5433945Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 20, 1992Date of Patent: July 18, 1995Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5358868Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 5, 1991Date of Patent: October 25, 1994Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5332583Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 5, 1991Date of Patent: July 26, 1994Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5244657Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogs are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: September 28, 1990Date of Patent: September 14, 1993Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5221618Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: September 30, 1991Date of Patent: June 22, 1993Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5085862Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunoganic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 23, 1988Date of Patent: February 4, 1992Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey